The Medicaid and CHIP Payment and Access Commission remains hopeful about the implementation of its recommendation to Congress that Medicaid programs be given the authority to require differential rebates for drugs approved through the US Food and Drug Administration’s accelerated approval pathway despite a current lack of enthusiasm, according to MACPAC executive director Anne Schwartz.
In its June report to Congress, MACPAC recommended that Congress boost the Medicaid base rebate for accelerated approval drugs...
